Orphan drugs and the NHSBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7525.1144-c (Published 10 November 2005) Cite this as: BMJ 2005;331:1144
Fairness in health care entails more than cost effectiveness
- Mark Sheehan (email@example.com), lecturer
- Centre for Professional Ethics, Keele University, Keele, Staffordshire ST5 5BG
EDITOR—When it comes to disease and illness, of course we should not value rarity.1 It certainly does not matter to those with rare disorders that they have a rare disease. What matters is how much the treatments cost.
The real question is how much we should value cost and cost effectiveness. Cost clearly matters to some degree, and we …